FDA Almost Ready To Close Door On Rx Versions Of MiraLAX
This article was originally published in The Tan Sheet
Executive Summary
FDA drug center Director Janet Woodcock says the agency “concluded there is no genuine and substantial issues that precludes the withdrawal” of approval of ANDAs for generic Rx polyethylene glycol 3350 products. But FDA is allowing firms with the ANDAs 60 days to again argue their positions.
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
New York Begins Restricting Sales Of Supplements, OTC Drugs For Weight Loss, Bodybuilding
Southern New York district judge rejects CRN’s arguments to block regulation from taking effect, but agrees with trade group and its members that they have standing to challenge the regulation. CRN complaint challenging law will continue in the district court.